Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus with low-dose ciclosporin A after basiliximab/ciclosporin A/prednisolone induction in pediatric renal transplant recipients
2006-001407-11Phase 3Completed
- Sponsor
- Medizinische Hochschule Hannover
- Start
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of everolimus in end-stage kidney disease (ESKD), Kidney allograft status (RTx) and chronic kidney disease (CKD), sponsored by Medizinische Hochschule Hannover. Primary endpoints: Graft function at 12 months post-transplantation and Time to first biopsy-proven acute rejection. Started May 2006; status: completed.
02
Drugs
everolimus
03
Conditions
end-stage kidney disease (ESKD)Kidney allograft status (RTx)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2006-001407-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001407-11.